Trial reportSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
TAR-0520, a new candidate in oncodermatology: Results of a phase 1 program in healthy volunteers.
Trial report in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTAR-0520 gel is a new topical formulation of brimonidine tartrate designed to prevent chemotherapy-induced skin toxicities. We report here the main outcomes of the phase 1 program which included two double-blind, randomized trials in healthy volunteers (TAR006 and TAR012) and were performed to evaluate the safety, local tolerability, pharmacokinetics, and pharmacodynamics (PD) of TAR-0520 gel.
methodIn TAR006, participants received four concentrations of TAR-0520 gel (0.5%, 0.75%, 1% and 1.5% of Brimonidine tartrate), placebo, or active comparator (Mirvaso® Galderma International, France) applied daily to the chest for 21 days, while TAR012 evaluated TAR-0520 gel 1% and 1.5% on the chest and face over the same duration. Local tolerance was assessed daily in both studies using mean cumulative irritation index and maximum irritation score as key endpoints. Skin blanching was assessed via chromameter-measured reductions in skin redness as a marker of vasoconstriction and product potency. In TAR006, systemic exposure to brimonidine tartrate was assessed from blood samples collected in a separate cohort treated with TAR-0520 gel 1%.
resultsOverall, 28 participants were randomized in TAR006 and 26 were randomized in TAR012. Both studies showed excellent local tolerance with 50 healthy volunteers reporting no evidence of irritation with any treatment and four patients reporting barely perceptible minimal erythema. No adverse events related to TAR-0520 gel were reported. Minimal systemic absorption was observed that was not considered to be clinically relevant. PD studies indicated dose-dependent vasoconstriction with once-daily use lasting over 24 h.
conclusionUnder the conditions of these studies, TAR-0520 gel presents a very favorable safety profile with little to no local irritation and insignificant systemic exposure. Allowing a superficial skin vasoconstriction over a period of 24 h, it offers a safe, patient-friendly, and adaptable topical solution. The 1.5% concentration was selected for further development and phase II trials for managing chemotherapy-related skin toxicities are in progress. REGISTRATION DETAILS: - TARIAN 006, 2023-504178-39-00 approved 24/08/203. - TARIAN 012, 2324CMCL096 approved 28/05/2024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.